The trial will compare the safety and efficacy of equecabtagene autoleucel versus standard therapies in r/r MM patients.
Japan’s move to conditionally approve two induced pluripotent stem cell derived therapies marks a significant development for ...
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a cell surface receptor ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced its 2025 annual results, highlighting a year of comprehensive, ...
Gilead acquired Arcellx to gain the development and marketing rights to anito-cel, for which GlobalData forecasts sales of ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive ...
SHANGHAI and NANJING, China and PLEASANTON, Calif., 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical ...
A good friend recently asked me if I had problems reconciling giving vaccines with my Catholic beliefs. I told him that there was absolutely no conflict, and ...
CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development ...
Discover Magazine on MSN
Over 20 years, one mouse was cloned for 58 generations — until the line collapsed
Learn how cloned mice survived for generations, why their DNA began to fail, and what the results reveal about genetic mutations, cloning limits, and long-term survival.
Presentations showcase progress in BioNTech's late-stage lung cancer programs, reinforcing the potential of the Company's differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...
Rapid Advancement Across Core R&D PipelineThe global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results